BIOCAD becomes Vector’s industrial partner to develop COVID-19 vaccine

BIOCAD becomes Vector’s industrial partner to develop COVID-19 vaccine

The biotechnology company BIOCAD has signed an agreement with the State Scientific Center for Virology and Biotechnology &laquoVektor» (Novosibirsk) on joint work on a vaccine based on rVSV against the COVID-19 virus. The vaccine development process has reached the final animal safety study stage. The cooperation agreement was signed by Dmitry Morozov (BIOCAD) and Rinat Maksyutov (Vector). According to the parties, the vaccine showed high promise in tests on laboratory animals, including lower primates. According to the agreement, the biotechnology company BIOCAD, as an industrial partner of the project, takes the costs and organizational efforts associated with conducting clinical trials of the rVSV vaccine, creating the technology for the release of the drug and the commercial production itself. Now, three research groups have been allocated to work on vaccines, in which more than 80 people specialized in virus work: from genetic engineering and virology to chemistry and bioinformatics. This approach provides a complete set of specialists necessary for all stages of the work on the vaccine, including production and clinical trials. We have been in a scientific collaboration with Novosibirsk Vector for a long time. and now we are an industrial partner of the rVSV vaccine development project. We are pleased to provide our partners with industrial release when clinical trials are completed. In my opinion, today is not the time for research teams to compete, we must combine our intellectual efforts. " Dmitry Morozov, Director General, BIOCAD Biotechnology Company Related Stories



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More